文献速递骨软组织肉瘤与黑色素瘤

瘤内Tilsotolimod联合伊匹木单抗在抗PD-1耐药黑色素瘤中驱动肿瘤缓解

Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma.
PubMed 文献 · Cancer Discov · 2021-03-11

ILLUMINATE-204 I/II期试验评估瘤内Tilsotolimod(TLR9激动剂)联合全身伊匹木单抗治疗抗PD-1耐药的晚期黑色素瘤。推荐II期剂量8 mg时总缓解率为22.4%,另有49%患者疾病稳定;局部IFNα基因特征快速诱导、树突状细胞成熟及T细胞克隆扩增与临床缓解相关。

要点

  • 抗PD-1耐药晚期黑色素瘤中,瘤内Tilsotolimod联合伊匹木单抗的ORR为22.4%(8 mg推荐II期剂量)。
  • 48.4%患者发生3/4级治疗中出现的不良事件。
  • 非注射病灶及预期对伊匹木单抗单药耐药的患者中观察到缓解。

核心结论

  • 瘤内Tilsotolimod联合伊匹木单抗在抗PD-1耐药晚期黑色素瘤中显示临床活性,包括非注射病灶和预期对伊匹木单抗单药耐药患者的缓解。

研究设计与样本

  • ILLUMINATE-204为I/II期试验,评估瘤内Tilsotolimod联合全身伊匹木单抗治疗抗PD-1耐药的晚期黑色素瘤患者。

主要发现

  • 所有患者中48.4%发生3/4级治疗中出现的不良事件。
  • 推荐II期剂量8 mg时总缓解率为22.4%,另有49%患者疾病稳定。
  • 非注射病灶及预期对伊匹木单抗单药耐药的患者中观察到缓解。
  • 局部IFNα基因特征快速诱导、树突状细胞成熟、抗原提呈标志物增强及T细胞克隆扩增与临床缓解相关。

关键数值与推荐

  • 推荐II期剂量为8 mg,该剂量下总缓解率为22.4%。

临床怎么用

  • 该联合方案为抗PD-1耐药晚期黑色素瘤提供潜在治疗选择,III期试验(NCT03445533)正在进行中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Many patients with advanced melanoma are resistant to immune checkpoint inhibition. In the ILLUMINATE-204 phase I/II trial, we assessed intratumoral tilsotolimod, an investigational Toll-like receptor 9 agonist, with systemic ipilimumab in patients with anti-PD-1- resistant advanced melanoma. In all patients, 48.4% experienced grade 3/4 treatment-emergent adverse events. The overall response rate at the recommended phase II dose of 8 mg was 22.4%, and an additional 49% of patients had stable disease. Responses in noninjected lesions and in patients expected to be resistant to ipilimumab monotherapy were observed. Rapid induction of a local IFNα gene signature, dendritic cell maturation and enhanced markers of antigen presentation, and T-cell clonal expansion correlated with clinical response. A phase III clinical trial with this combination (NCT03445533) is ongoing. SIGNIFICANCE: Despite recent developments in advanced melanoma therapies, most patients do not experience durable responses. Intratumoral tilsotolimod injection elicits a rapid, local type 1 IFN response and, in combination with ipilimumab, activates T cells to promote clinical activity, including in distant lesions and patients not expected to respond to ipilimumab alone.This article is highlighted in the In This Issue feature, p. 1861.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Haymaker C, Johnson DH, Murthy R, et al. Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma. Cancer Discov. 2021. PMID: 33707233. doi:10.1158/2159-8290.CD-20-1546

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。